

Can't find Merilog at your pharmacy? Here are practical tools and tips to locate Merilog (insulin aspart-szjj) in stock near you — including real-time availability search.
You've got your prescription for Merilog (insulin aspart-szjj). You drive to the pharmacy. And then you hear the words no one with diabetes wants to hear: "We don't have that in stock."
It's frustrating — and when you're dealing with insulin, it can feel urgent. Merilog is the first rapid-acting insulin biosimilar, approved by the FDA in February 2025 and made available in pharmacies starting July 2025. While it's an exciting addition to the insulin market, availability can still be spotty depending on where you live.
Here are three proven strategies to find Merilog in stock — plus what to do if you still come up empty.
The fastest way to find Merilog in stock is to use Medfinder. Instead of calling pharmacy after pharmacy, Medfinder lets you search for medication availability near you in real time.
Here's how it works:
It's free, fast, and saves you the headache of making a dozen phone calls. You can also learn more about checking pharmacy stock for Merilog.
If the big chain pharmacies near you don't stock Merilog, don't stop there. Independent pharmacies and specialty pharmacies are often more flexible about ordering medications that aren't part of their standard inventory.
Here's why independent pharmacies can be a better bet:
Don't have an independent pharmacy nearby? Check Medfinder — it includes independent pharmacies in its search results.
Pharmacy inventory fluctuates throughout the week. Here are a few timing tips that can improve your odds:
If you've tried these strategies and still can't locate Merilog, here are some backup options:
Talk to your prescriber. Your doctor or endocrinologist can help you explore alternatives or contact Sanofi directly about supply in your area. They may also be able to provide samples to bridge any gaps. Read about finding a doctor who prescribes Merilog.
Consider therapeutic alternatives. While Merilog is your prescribed medication, other rapid-acting insulins like NovoLog, Humalog, Admelog, or Apidra work similarly. Your doctor can determine if switching temporarily makes sense for you. Learn more about alternatives to Merilog.
Contact Sanofi directly. Sanofi's patient support line can help you locate pharmacies with Merilog in stock and connect you with their savings programs. Call 1-888-847-4877 or visit sanofipatientconnection.com.
Ask about mail-order pharmacy. Some insurance plans offer mail-order pharmacy options that may have better access to Merilog than your local retail pharmacy. This can also be more convenient for ongoing prescriptions.
Merilog's availability challenges aren't unusual for a newly launched biosimilar. The insulin market is going through significant changes: Novo Nordisk discontinued its unbranded insulin aspart at the end of 2025, and Fiasp pen shortages have continued into early 2026. These shifts have increased demand for alternatives like Merilog faster than Sanofi expected.
The good news? Supply is improving. As more insurance plans add Merilog to their formularies and Sanofi expands production, finding it at your local pharmacy should get easier throughout 2026. For more background, read about why Merilog is hard to find in 2026.
Finding Merilog shouldn't feel like a scavenger hunt — but right now, it sometimes does. The key is being proactive: use Medfinder to check real-time availability, explore independent pharmacies, time your refills wisely, and don't hesitate to lean on your healthcare team for support.
Merilog is an affordable, effective option for managing diabetes — and with a little effort, you can get it in your hands.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.